protein uptake accompanied by an increased resistance to microsomal digestion. Remarkably, rFlaA:Betv1 induced activation of mammalian target of rapamycin, which increased the metabolic activity of the stimulated mDCs. rFlaA:Betv1-mediated IL-10 secretion, but not proinflammatory cytokine secretion, was inhibited by rapamycin in mDCs. Conclusion: These results provide evidence that mammalian target of rapamycin is a key player involved in prevention of T H Although the introduction of vaccines has drastically improved our prevention options for many different types of diseases, the search for more efficacious vaccines to combat or prevent diseases with a significant effect on public health, such as infections, cancer, or allergies, remains a major task.
Pure antigen preparations, which are often weakly immunogenic, need to be adjuvanted to induce robust immune responses. 1 Here the Toll-like receptor (TLR) 5 ligand flagellin, 2 a bacterial motility protein forming the body of the bacterial flagellum, has demonstrated its potential as mucosal adjuvant to mediate protective immunity. [3] [4] [5] One major advantage of flagellin is its protein nature, allowing for the efficient generation of fusion constructs of flagellin and antigen using recombinant DNA technologies. Such fusion proteins combine antigen and adjuvant (flagellin) into a single molecule, allowing for efficient targeting of antigens to and simultaneous activation of TLR5 1 antigen-presenting cells (APCs). 5 A growing body of studies suggest that fusion proteins incorporating flagellin efficiently induce humoral and cellmediated immunity against a variety of antigens in animal models [6] [7] [8] and might have potential as vaccine candidates for many diseases, including influenza, [9] [10] [11] poxvirus, 12 West Nile virus, 8 tetanus, 13 Pseudomonas species infection, 14 and allergies. 6 Additionally, flagellin-containing fusion proteins are currently in clinical trials for the prevention of influenza infection, where they were proven to be both safe and efficacious in inducing protective immune responses. 15, 16 This vaccine combining flagellin C from Salmonella species with peptides derived from the influenza antigen M2e was shown to efficiently induce antibody responses against the otherwise poorly immunogenic M2e 15 without inducing serious adverse events in healthy young adults. 16 Moreover, Kitzm€ uller et al recently described the enhanced immunogenicity, reduced allergenicity, and intrinsic adjuvanticity of flagellin C:Bet v 1 fusion proteins in human monocyte-derived dendritic cells (DCs) and T cells from allergic patients. 17 The results obtained by Treanor et al, 16 Turley et al, 15 and Kitzm€ uller et al show that such flagellin:allergen fusion proteins have similar immunemodulating effects on both mouse and human immune cells and therefore a relevance as vaccines for future human application.
However, despite their well-described immune-activating potential, the mechanisms by which such fusion proteins exert their immune-modulating effects are less well understood. The protective immune responses induced upon application of a fusion protein consisting of Salmonella flagellin C and Plasmodium vivid circumsporozoite protein required TLR5/myeloid differentiation primary response gene-88 (MyD88) signaling. 18 Accordingly, stimulation of CD11c 1 TLR5 1 cells and signaling through TLR5 was essential for the adjuvant activity of a flagellin-ovalbumin (OVA) fusion protein. 19 Recently, we reported that a fusion protein consisting of flagellin A (FlaA) from Listeria monocytogenes and OVA efficiently protected mice against OVA-induced intestinal allergy. 6 The strong immune-modulating capacity of the fusion protein was accompanied by enhanced uptake into CD11c 1 myeloid dendritic cells (mDCs), likely facilitated by protein aggregation, resulting in different processing of the fused antigen by mDCs, as well as stronger cell activation. 20 However, the detailed mechanisms by which these potent vaccine candidates modulate immune responses are still unclear.
The mammalian target of rapamycin (mTOR) is a serine/ threonine protein kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase protein family, which forms a multiprotein complex with the proteins mammalian lethal with SEC13 protein 8 (mLST8), proline-rich Akt substrate of 40 kDa (PRAS40), Raptor, G protein b-subunit-like protein, pronounced ''Gable'' (GbL), and DEP domain-containing mTOR-interacting protein (DEPTOR). 21 The mTOR1 complex acts as a master regulator of cellular growth, sensing and integrating diverse nutritional and environmental cues, including growth factors, energy levels, cellular stress, and amino acids. 21 It links these signals to the promotion of cellular growth by phosphorylating substrates; potentiating anabolic processes, such as mRNA translation and lipid synthesis; or limiting catabolic processes, such as autophagy. 21 Recently, mTOR1 activation was implicated to have important functions in immunologic processes, such as the maturation and function of APCs, as well as T-cell differentiation. 22 Here we investigated the potency and immune-modulating mechanism of a fusion protein consisting of the TLR5 ligand FlaA from L monocytogenes and the major birch pollen allergen Bet v 1, causing respiratory allergy in millions of persons. The fusion protein (recombinant flagellin A [rFlaA]:Betv1) displayed strong immune-modulating properties both in vivo and in vitro characterized by secretion of both proinflammatory and anti-inflammatory cytokines from murine mDCs, as well as PBMCs from patients with birch allergy.
Mechanistically, we showed that stimulation with rFlaA:Betv1 resulted in an increased metabolic activity of the stimulated mDCs mediated by activation of mTOR. Moreover, induction of antiinflammatory IL-10 secretion by rFlaA:Betv1, but not proinflammatory cytokine secretion in mDCs, was inhibited by rapamycin and therefore dependent on mTOR activation, showing that immune-modulatory cytokine secretion induced by this vaccine candidate was linked to activation of mDC metabolism.
METHODS

Generation of recombinant proteins
rFlaA from L monocytogenes (accession no, NC_003210) was generated according to the method of Sch€ ulke et al, 23 and recombinant birch pollen allergen Bet v 1 (accession no, X15877.1) was generated according to the method of Siebeneicher et al. 24 The fusion protein of rFlaA and rBet v 1 (rFlaA:Betv1) was generated according to the method of Sch€ ulke et al 23 by means of cDNA fusion with cDNAs of both rFlaA and rBet v 1 as templates. All proteins displayed a purity of greater than 99%; correct folding of secondary structure elements, as determined by using circular dichroism spectroscopy; and an endotoxin content of 1.14 pg/mg protein (rFlaA), less than 0.48 pg/mg protein (rBet v 1), and 1.7 pg/mg protein (rFlaA:Betv1), respectively (data not shown).
Mice
BALB/c, C57BL/6, TLR5 2/2 , and MyD88 2/2 mice (on the C57BL/6
background; all from Jackson Laboratories, Bar Harbor, Me) were bred at the animal facility of the Paul-Ehrlich-Institut under specific pathogen-free conditions. All animal experiments were performed in compliance with the German animal protection law (granting authority: RP Darmstadt, Germany; approval no. F107/131).
In vivo birch pollen allergy model
For the animal model of birch pollen sensitization, BALB/c mice were vaccinated intraperitoneally twice in 1-week intervals with PBS, rFlaA plus rBet v 1, or rFlaA:Betv1 (all equimolar to 10 mg rBet v 1 per mouse in 200 mL of PBS). One week after the second vaccination, mice were sensitized by means of 2 intraperitoneal injections of rBet v 1 plus aluminum hydroxide (alum; 10 mg of rBet v 1 plus 2 mg of alum; Thermo Scientific Pierce, Dreieich, Germany) 2 weeks apart. Two weeks after the second sensitization, mice were sacrificed, and 3 3 10 6 splenocytes were restimulated with concanavalin A (Sigma-Aldrich, Taufkirchen, Germany) or either 0.1, 1, or 10 mg/mL rBet v 1 for 72 hours and analyzed for cytokine secretion by means of ELISA with BD OptEIA ELISA Sets (BD Biosciences, Heidelberg, Germany). Bet v 1-specific IgG 1 , IgG 2a , and IgE levels were determined by means of ELISA, according to the method of Siebeneicher et al. 24 Mediator release from RBL-2H3 cells was performed by using sera from the final bleed, according to the method of Sch€ ulke et al. 6 In vitro generation of mouse bone marrow-derived DCs, stimulation, and flow cytometry Mouse mDCs were generated, as described previously. 23 On day 8, mDCs were seeded at 3.2 3 10 5 cells/mL in 24-well plates (Thermo Scientific, Waltham, Mass) and stimulated with the indicated equimolar concentrations of rFlaA, rBet v 1, rFlaA plus rBet v 1, or rFlaA:Betv1 for 24 hours. Supernatants were analyzed for cytokine secretion by means of ELISA with BD OptEIA ELISA Sets (BD Biosciences). The activation status and viability of CD11b 
Experiments with human material
Allergen-specific T-cell lines were expanded according to the method of Kitzm€ uller et al 25 and stimulated with equimolar amounts Bet v 1, rFlaA, or rFlaA:Betv1. After 48 hours, proliferative responses were assessed by means of incorporation of tritiated thymidine. The study was approved by the local ethics committee (EK 029/2006). Blood donors provided written informed consent.
Inhibitors
For inhibitor experiments, cells were preincubated with the indicated amounts of rapamycin, chloroquine, 2-deoxyglucose (2-DO), wortmannin, FK506 (all from InvivoGen, Toulouse, France), or cytochalasin A (in dimethyl sulfoxide; Sigma-Aldrich) for 90 minutes and subsequently stimulated with equimolar amounts of rFlaA plus rBet v 1 or rFlaA:Betv1 for either 30 minutes (Western blot), 24 hours (ELISA), or 72 hours (analysis of cell metabolic state).
TLR5 activation assay
TLR5 activation assays using HEK 293 cells stably transfected with the murine TLR5 (InvivoGen) were performed according to the method of Sch€ ulke et al. 23 Antigen uptake assays and microsomal digestion Antigen uptake assays using proteins labeled with the Alexa Flour 488 Microscale Protein Labeling Kit (Invitrogen, Carlsbad, Calif) were performed according to the method of Sch€ ulke et al. 20 More information can be found in the Methods section in this article's Online Repository at www.jacionline.org. Simulation of intracellular processing by means of microsomal digestion was performed according to the method of Sch€ ulke et al. 20 
Western blotting
For Western blot experiments, mDCs were starved in RPMI 1640 plus 10% FCS (Sigma-Aldrich) with or without the indicated inhibitor concentrations and cultured for 3 hours at 378C in a 5% CO 2 
Statistical analysis
Statistical analysis was performed with GraphPad Prism software (version 6 to version 8; GraphPad Software, La Jolla, Calif) for Macintosh or Windows by using 2-way ANOVA tests with CIs adjusted for multiple comparisons, according to either Bonferroni or Tukey tests. For statistically significant results, the following convention was used: *P < .05, **P < .01, and ***P < .001.
A more comprehensive description of the materials and methods used in this article can be found in the Methods section in this article's Online Repository.
RESULTS
Vaccination with rFlaA:Betv1 prevents Bet v 1-specific IgE production Effects of rFlaA:Betv1 treatment before Bet v 1 sensitization were analyzed in an experimental mouse model of allergic sensitization to birch pollen (Fig 1, A) . (Fig 1, B and C) or 5 donors with birch pollen allergy (Fig 1, E) . For statistically significant results, the following convention was used: *P < .05, **P < .01, and ***P < .001.
sensitized but nonvaccinated mice (PBS/B/A) or animals vaccinated with the mixture of both proteins (rFlaA plus rBet v 1/B/A; Fig 1, B) . Moreover, Bet v 1-specific IgE production observed in nonvaccinated mice and mice vaccinated with the mixture of both proteins was significantly reduced in rFlaA: Betv1-vaccinated mice, Bet v 1-specific IgG 1 levels were not different between rBet v 1-sensitized groups after sensitization at day 41, and rFlaA:Betv1-vaccinated mice showed significantly increased rBet v 1-specific IgG 1 levels after vaccination on day 14 (Fig 1, B) . Therefore vaccination with rFlaA:Betv1 resulted in strongly enhanced Bet v 1-specific IgG 2a /IgE ratios compared with those in either nonvaccinated mice (PBS/B/A) or animals vaccinated with rFlaA1rBet v 1 (rFlaA1rBet v 1/B/A; see Fig E1, A, in this article's Online Repository at www.jacionline.org). Accordingly, Bet v 1-induced b-hexosaminidase release from RBL-2H3 cells passively sensitized with the sera of rFlaA:Betv1-vaccinated mice was significantly reduced compared with sera of nonvaccinated animals, which was not observed for animals vaccinated with rFlaA1rBet v 1 (see Fig E1, B) .
In line with these results, splenocyte cultures of animals vaccinated with rFlaA:Betv1 showed significantly reduced production of IL-5 on restimulation with rBet v 1 compared with either nonvaccinated animals or animals vaccinated with rFlaA plus rBet v 1 (Fig 1, C) . Here, on restimulation with rBet v 1, IL-13 levels of splenocytes vaccinated with rFlaA:Betv1 were not different from levels observed from splenocytes vaccinated with rFlaA plus rBet v 1, whereas IL-10 levels were slightly reduced (Fig 1, C) .
Immune-modulating effects on systemic secretion of proinflammatory and anti-inflammatory cytokines were analyzed in BALB/c mice 7 hours after vaccination (see Fig E2 in this article's Online Repository at www.jacionline.org). Here rFlaA:Betv1 induced substantially higher levels of IL-10 secretion in 3 of 4 mice and significantly higher IL-6 secretion than all other control mice (see Fig E2) . This shows that conjugation of rFlaAwith Bet v 1 increases immunogenicity in comparison with equimolar amounts of rFlaA, rBet v 1, or rFlaA 1 Bet v 1.
To test whether the observed immune-modulatory effects of rFlaA:Betv1 can be transferred to human cells, we stimulated PBMCs from donors with birch pollen allergy with equimolar amounts of rFlaA or rFlaA:Betv1. rFlaA:Betv1 stimulation resulted in higher IL-10 secretion for all tested donors (Fig 1, D; for dose dependency see Fig E3 in this article's Online Repository at www.jacionline.org). When 3 Bet v 1-and 3 birch pollen-specific human T-cell lines were stimulated with equimolar amounts of rFlaA, rBet v 1, or rFlaA:Betv1, Bet v 1 induced cell proliferation in all 6 cell lines tested, whereas rFlaA stimulation did not result in detectable proliferation (Fig 1, E) . Interestingly, compared with equimolar amounts of Bet v 1, stimulation with rFlaA:Betv1 resulted in lower levels of proliferation in 3 of 3 Bet v 1-specific Tcell lines and 2 of 3 birch pollen-specific T-cell lines (Fig 1, E) .
Therefore rFlaA:Betv1 strongly affects the innate and adaptive immune responses in mice and human subjects and might serve as an attractive vaccine to prevent allergic sensitization.
rFlaA:Betv1 induces proinflammatory and anti-inflammatory responses from mDCs in vitro
To analyze how rFlaA:Betv1-mediated dendritic cell (DC) activation contributed to the observed prevention of birch pollen allergy, we stimulated bone marrow-derived murine mDCs with rFlaA:Betv1 and the respective controls (Fig 2, A , and see Fig E4 in this article's Online Repository at www.jacionline.org). Here rFlaA:Betv1, but not the equimolar mixture of both proteins or both proteins alone, induced a significantly higher secretion of both proinflammatory (IL-1b and IL-6) and anti-inflammatory (IL-10) cytokines from BALB/c-derived mDCs (Fig 2, A) . IL-12p70 secretion was slightly higher from rFlaA:Betv1-stimulated mDCs, but the differences did not reach statistical significance. In line with this, analysis of the activation status of the stimulated mDCs revealed that stimulation with rFlaA:Betv1 strongly upregulated the costimulatory molecules CD40 (see Fig E4) and CD69 (data not shown), as well as the coinhibitory molecules B7-H4 and B7-H1 on mDCs and B7-DC to a lesser degree (see Fig E4) . Here stimulation with equimolar protein amounts of rFlaA plus Bet v 1, as well as both rFlaA and Bet v 1 alone, did not result in upregulation of coinhibitory molecules and induced only low levels of CD40 expression (see Fig E4) .
rFlaA:Betv1 suppresses both Bet v 1-specific T H 1 and T H 2 responses ex vivo
To analyze the effect of rFlaA:Betv1 on allergen-specific immune responses, we performed ex vivo coculture experiments using mDCs with T H 2-biased Bet v 1-specific CD4 1 T cells (Fig 2, B ). In cocultures with T H 2-biased CD4 1 T cells from Bet v 1 plus alum-sensitized mice, rFlaA:Betv1-pulsed mDCs significantly suppressed Bet v 1-induced secretion of the T H 2 cytokines IL-13 (Fig 2, B) and IL-5 (see Fig E5 in this article's Online Repository at www.jacionline.org). Here IL-4 levels within cocultures were very low, and differences did not reach statistical significance (data not shown). Suppression of T H 2 cytokine secretion was accompanied by a significantly increased secretion of the immunosuppressive cytokine IL-10 (compared with stimulation with equimolar amounts of Bet v 1). In this experimental setting, IL-10 was produced by mDCs rather than T cells (data not shown). Here levels of the Bet v 1-induced T H 1 cytokine IL-2 were retained on simultaneous costimulation with rBet v 1 plus rFlaA:Betv1, whereas IFN-g levels were significantly increased upon stimulation with rFlaA:Betv1 either alone or in combination with rBet v 1 (Fig 2, B) .
Interestingly, compared with stimulation with rFlaA:Betv1, stimulation with the mixture of rFlaA plus rBet v 1 induced neither IL-10 nor IFN-g secretion and therefore was not sufficient to suppress rBet v 1-induced T H 2 cytokine production (Fig 2, B , and see Fig E5) .
Therefore rFlaA:Betv1 potently suppressed T H 2-biased allergen-specific immune responses, possibly mediated by mDC-derived IL-10 secretion.
rFlaA:Betv1 aggregates are taken up more strongly than the mixture of both proteins
To analyze the mechanisms of rFlaA:Betv1-mediated immune modulation, we compared the ability of rFlaA and the rFlaA:Betv1 fusion protein to activate TLR5 by using HEK reporter cells stably transfected with murine TLR5 (Fig 3, A) . Here no significant differences in the capacity of rFlaA and rFlaA:Betv1 to activate TLR5 were detectable (Fig 3, A) . As expected, rBet v 1 did not induce IL-8 secretion from mTLR5-transfected HEK 293 cells (Fig 3, A) , and no tested protein resulted in IL-8 secretion from HEK 293 WT cells lacking TLR5 expression (Fig 3, A) . Further protein characterization showed single bands of the expected molecular size under denaturing/reducing conditions for all proteins tested (Fig 3,  B) , whereas native DISC-PAGE revealed rFlaA and rFlaA:Betv1 to form high-molecular-weight aggregates (Fig 3, B) . Interestingly, for rFlaA, monomeric, dimeric, and aggregated forms were observed under native conditions, whereas for rFlaA:Betv1, only high-molecular-weight aggregates were detected (Fig 3, B) , suggesting that rFlaA:Betv1 could mediate its stronger mDC activation through increased uptake of protein aggregates. Accordingly, Alexa Fluor 488-labeled rFlaA:Betv1 displayed a higher uptake into mDCs compared with rFlaA and rBet v 1 either alone or as a mixture (Fig 3, C) . Interestingly, higher uptake rates of rFlaA:Betv1 were independent of TLR5 expression because comparable levels of protein uptake were observed between C57BL/6 and TLR5-deficient mDCs (Fig 3,  D) . Accordingly, preincubation of mDCs with inhibitors of actin polymerization (cytochalasin A) and lysosomal acidification/ TLR ligand-TLR binding (chloroquine 26 ) dose-dependently inhibited uptake of the fusion protein (Fig 3, E) , as well as both rFlaA:Betv1-induced IL-10 and IL-6 secretion (Fig 3, F) , suggesting that increased uptake and processing of the fusion protein are involved in the observed mDC activation.
To further analyze the processing of the different proteins by mDCs, we performed microsomal digestion assays, which test the stability of proteins toward lysosomal proteases. Upon incubation with lysate from isolated microsomes, both rFlaA and rBet v 1 were quickly degraded within 3 to 5 hours, whereas intact rFlaA:Betv1 molecules were still detectable after 12 hours of digestion (Fig 3, G) .
rFlaA:Betv1 activates cell metabolism in stimulated mDCs
Next, we intended to determine the mechanism of rFlaA: Betv1-induced IL-10 secretion in vitro. Mouse mDC cultures stimulated with rFlaA:Betv1 for up to 72 hours revealed a pronounced discoloration of culture media, which was less pronounced in cells stimulated with the equimolar mixture of both proteins (Fig 4, A) . This result suggests a strong metabolic activity of mDCs stimulated with rFlaA:Betv1. A marked increase in overall cellular metabolism resulting from a predominant production of energy by a high rate of glycolysis and lactic acid fermentation is known as the Warburg effect. 27 Notably, the rFlaA: Betv1-induced Warburg effect could be inhibited by addition of the irreversible inhibitor of glucose metabolism 2-DO (Fig 4,  A-C) . Further analysis of the cellular redox status in rFlaA:Betv1-stimulated mDCs revealed that rFlaA:Betv1 stimulation resulted in a significant accumulation of NADH in mDCs compared with unstimulated mDCs or mDCs stimulated with rFlaA plus rBet v 1 (Fig 4, B) , which is characteristic of the Warburg effect. NADH accumulation was not observed in mDCs stimulated with the mixture of both proteins (Fig 4, B) . Consequently, rFlaA:Betv1-stimulated mDCs displayed significantly reduced NAD 1 /NADH ratios compared with cells stimulated with the equimolar mixture of both single proteins (Fig 4, B) . The disruption of glucose metabolism by 2-DO dose-dependently reduced the rFlaA:Betv1-induced accumulation of NADH and increased NAD 1 /NADH ratios to levels observed in mDCs stimulated with the mixture of both proteins (Fig 4, B) .
Accordingly, mDCs stimulated with rFlaA:Betv1, but not rFlaA plus rBet v 1, displayed a significantly increased For statistically significant results, the following convention was used: *P < .05, **P < .01, and ***P < .001.
consumption of glucose from the culture medium (Fig 4, C) and a significant increase in overall metabolic activity (Fig 4, C) . Both the rFlaA:Betv1-induced glucose consumption and metabolic rates were significantly and dose-dependently inhibited by 2-DO pretreatment (Fig 4, C) . When analyzing mDC-derived cytokine secretion in the presence or absence of 2-DO-mediated inhibition of glycolysis, we observed that 2-DO dose-dependently and significantly inhibited rFlaA:Betv1-induced IL-10 and proinflammatory IL-12p70 secretion, whereas 2-DO had either no (IL-1b) or moderate (IL-6) effect on other proinflammatory cytokines tested (Fig 4, D) .
rFlaA:Betv1-induced IL-10 secretion by mDCs is mediated by mTOR1 activation Because we observed an enhanced cell metabolism upon stimulation with rFlaA:Betv1, we investigated further the pathways potentially involved in the induced Warburg effect. Expression profiling performed with lysates of stimulated mDCs revealed PRAS40 and mTOR to be phosphorylated after stimulation with rFlaA:Betv1 (data not shown).
To verify the role of mTOR in FlaA fusion protein-mediated cell activation, we stimulated mDCs with equimolar amounts of rFlaA plus rBet v 1 or rFlaA:Betv1 and checked for phosphorylation of the components of the mTOR1 complex in mDCs (Fig 5, A) . Stimulation with rFlaA:Betv1, but not the equimolar mixture of both proteins, induced phosphorylation of PRAS40 and mTOR but not Raptor (Fig 5, A , and see Fig E6 in this article's Online Repository at www.jacionline.org), which is consistent with activation of the mTOR1 complex in rFlaA:Betv1-stimulated mDCs. In accordance with these results, strong phosphorylation of the mTOR target protein p70S6 kinase at residue Thr389, but not Ser371, was observed only in cells stimulated with rFlaA:Betv1 (Fig 5, A) . No differences in phosphorylation of the mTOR target protein 4E-BP1 were observed between cells stimulated with rFlaA plus rBet v 1 or rFlaA:Betv1 (Fig 5, A) .
Subsequently, the role of the mTOR1 complex in the immune-modulating effects of rFlaA:Betv1 was verified by using rapamycin, a specific inhibitor of mTOR1 activation. 21 Rapamycin in concentrations of up to 10 nmol/L was shown to be nontoxic for mDCs (Fig 5, B) . In rFlaA:Betv1-stimulated mDCs, preincubation with rapamycin dose-dependently inhibited mTOR phosphorylation by approximately 40% and p70S6 kinase (Thr389) phosphorylation almost completely, whereas levels of H3 histone and nonphosphorylated mTOR were unchanged (Fig 5, C) .
Interestingly, upregulation of TLR5 observed on mDCs after stimulation with rFlaA:Betv1 was dose-dependently inhibited by Fig 3, C and D) or TLR5 2/2 (Fig 3, D) bone marrow-derived mDCs (C57BL/6) were stimulated with the indicated protein concentrations for 15 minutes and subsequently analyzed for protein uptake into CD11b
2 mDCs by flow cytometry. E and F, Bone marrowderived mDCs were preincubated for 2 hours with the indicated inhibitor concentrations, subsequently stimulated with 2.74 mg/mL rFlaA:Betv1, and checked for protein uptake 15 minutes (Fig 3, E) and cytokine secretion 24 hours after stimulation (Fig 3, F) . G, Microsomal digestion of the proteins was performed for the indicated durations, and protein degradation was monitored by means of SDS-PAGE. P, Proteins without microsomes. Data are mean 6 SD results of 3 (Fig 3, A) to 4 (Fig 3, E and F) independent experiments or representative results of 2 (Fig 3, D and G) to 3 (Fig 3, B and C) independent experiments. ***P < .001.
rapamycin preincubation, whereas CD40 expression remained unaffected (Fig 5, D) . This result indicates that the observed TLR5 upregulation upon stimulation with rFlaA:Betv1 is an mTOR-dependent downstream event.
Next, we determined the influence of mTOR1 inhibition on rFlaA:Betv1 fusion protein-mediated, mDC-derived cytokine secretion (Fig 5, E) . Pretreatment with rapamycin resulted in dose-dependent and significant inhibition of IL-10 secretion from mDCs, whereas IL-12p70 secretion was significantly enhanced when mDCs were pretreated with higher doses of rapamycin (Fig 5, E) . Rapamycin pretreatment had no significant effect on the rFlaA:Betv1-induced secretion of IL-1b or IL-6 from mDCs (Fig 5, E) .
Concordantly, pretreatment of mDCs with the PI3K antagonist wortmannin, which suppresses upstream events in activation of the mTOR1 complex, also inhibited rFlaA:Betv1-induced IL-10 production and resulted in an approximately 2.5-fold increase in IL-12p70 production (see Fig E7 in this article' s Online Repository at www.jacionline.org). Moreover, wortmannin pretreatment had no effect on rFlaA:Betv1-induced secretion of IL-1b or IL-6 (see Fig E7) . In contrast, the calcineurin inhibitor FK506, which has no influence on the activation and function of the mTOR1 complex, 28 inhibited the rFlaA:Betv1-induced IL-12p70 secretion but not IL-10, IL-1b, or IL-6 production (see Fig E8 in this article' s Online Repository at www.jacionline.org).
In summary, we showed that stimulation of mDCs with rFlaA:Betv1 (but not the equimolar mixture of both proteins) resulted in a shift in cellular metabolism toward high rates of glycolysis, followed by lactic acid fermentation (the Warburg effect). This shift in cellular metabolism likely is mediated by activation of mTOR1, which promoted IL-10 secretion.
rFlaA:Betv1-induced Warburg effect is independent of TLR5 expression
To further analyze the signaling pathways contributing to rFlaA:Betv1-mediated mDC activation, we compared activation of mDC metabolism and cytokine secretion between C57BL/6, TLR5-deficient, and MyD88-deficient mDCs (Fig 6) . In line with our observation that the rFlaA:Betv1-induced TLR5 upregulation was downstream of and regulated by mTOR (Fig 5, D) , the rFlaA:Betv1-induced Warburg effect was independent of TLR5 expression (Fig 6, A and B) but dependent on mTOR activation. In contrast to this, the rFlaA:Betv1-induced Warburg effect was significantly reduced in MyD88-deficient mDCs (Fig 6, A and  B) . Rapamycin and 2-DO dose-dependently inhibited the rFlaA:
Betv1-induced Warburg effect in mDCs from all tested mouse strains (Fig 6, A and B) .
Likewise, glucose consumption and metabolic rate were comparable in C57BL/6 and TLR5 2/2 mDCs but significantly reduced in MyD88 2/2 mDCs (Fig 6, C and D) . Pretreatment of mDCs with rapamycin or 2-DO dose-dependently inhibited glucose consumption and therefore metabolic activity independently of TLR5 expression (Fig 6, C and D) .
In addition, no difference in rFlaA:Betv1-induced cytokine secretion was detected when comparing C57BL/6 and TLR5 2/2 mDCs (Fig 6, E) . While stimulation of MyD88 2/2 mDCs with rFlaA:Betv1 resulted in no detectable secretion of the tested cytokines (Fig 6, E) , in both C57BL/6 and TLR5 2/2 mDCs, rFlaA:Betv1-induced IL-10 secretion was dose-dependently inhibited by rapamycin, whereas IL-12p70 secretion was enhanced. Here rFlaA:Betv1-induced IL-1b and IL-6 secretion were not influenced by rapamycin pretreatment. In contrast, pretreatment with 2-DO inhibited the rFlaA:Betv1-induced secretion of all investigated cytokines (Fig 6, E) . No IL-12p70 secretion was detected upon pretreatment with higher doses of 2-DO (1 and 10 mmol/L). These results support the view that 2-DO results in general inhibition of cell metabolism, whereas mTOR inhibition by rapamycin specifically inhibits rFlaA:Betv1-induced anti-inflammatory cytokine secretion.
Suppression of IL-12p70 production correlated with high levels of IL-10 production. 28 
DISCUSSION
Flagellin antigen fusion proteins are thought to hold great potential as vaccines to improve treatment/prevention of many diseases. However, their mode of action is less understood. For the first time, the present study describes the mechanism of immune modulation of a novel vaccine candidate consisting of the TLR5 ligand flagellin and the major birch pollen allergen Bet v 1 to be dependent on mTOR-mediated activation of mDC metabolism.
We found that rFlaA:Betv1, but not the mixture of both proteins, induced a strong innate immune response characterized by secretion of both proinflammatory and anti-inflammatory cytokines from mDCs. This dichotomy was also observed with respect to upregulation of both costimulatory and coinhibitory molecules on the surfaces of mDCs only upon stimulation with the fusion protein. rFlaA:Betv1 induced strong IL-10 secretion from mDCs and suppressed T H 2 responses from T H 2-biased T cells isolated from Bet v 1 plus alum-sensitized mice while retaining IL-2 and inducing IFN-g production. Here the nonfused mixture of both proteins did not have comparable immune-modulating effects. (Fig 5, C) , TLR5 and CD40 upregulation by means of flow cytometry (median fluorescence intensity [MFI] values indicated in the respective plots) 24 hours after stimulation (Fig 5, D) , and cytokine secretion 24 hours after stimulation (Fig 5, E) . Data are mean 6 SD results of 3 independent experiments (Fig 5, B, C , and E) and representative results of 2 independent experiments (Fig 5, A and D) . RLU, Relative light unit. ***P < .001.
Previous in vitro results suggested that IL-10 might be important for FlaA fusion protein-mediated immune modulation. 6 Here we provide evidence that in vivo application of the rFlaA:Betv1 fusion protein resulted in high levels of IL-10 production in 3 of 4 mice tested. Moreover, we show that applying rFlaA:Betv1 twice was sufficient to prevent allergic sensitization characterized by significantly reduced rBet v 1-specific IgE levels and increased Bet v 1-specific IgG 2a /IgE ratios. Application of rFlaA:Betv1 in human allergen-specific T-cell lines resulted in reduced, although statistically not significant, proliferation compared with application of Bet v 1 in 5 of 6 tested T-cell lines. Moreover, we observed a strong IL-10 secretion from PBMCs isolated from patients with birch pollen allergy, suggesting that rFlaA: Betv1-mediated IL-10 production might be a conserved mechanism in murine and human cells and therefore rFlaA:Betv1 might be a suitable vaccine candidate for the prevention of birch pollen allergy.
The enhanced immune-modulatory effect of rFlaA:Betv1 cannot be explained by TLR5-binding properties alone. Although no differences in the capacity to activate TLR5 were FIG 6 . rFlaA:Betv1-induced Warburg effect is independent of TLR5. C57BL/6, TLR5 2/2 , or MyD88 2/2 bone marrow-derived mDCs were stimulated with rFlaA:Betv1 in the presence or absence of the indicated amounts of rapamycin or 2-Deoxy-glucose (2-DO) for 72 hours. A and B, The induced Warburg effect is depicted (Fig 6,  A) and quantified (Fig 6, B) . C and D, Glucose consumption by the stimulated mDCs is determined (Fig 6, C) , and the calculated metabolic rate is depicted (Fig 6, D) . E, Cytokine secretion was determined 72 hours after stimulation by means of ELISA. Data are mean 6 SD results from 3 independent experiments. For statistically significant results, the following convention was used: *P < .05, **P < .01, and ***P < .001.
detected between rFlaA and rFlaA:Betv1, both proteins displayed different degrees of high-molecular-weight aggregation. The predominant existence of high-molecular-weight rFlaA: Betv1 aggregates led to a stronger uptake of rFlaA:Betv1 and mediated enhanced mDC activation. Notably, internalization of rFlaA:Betv1 into mDCs was mostly TLR5 independent, whereas rFlaA:Betv1-induced cytokine secretion was inhibited by blocking actin polymerization, suggesting that TLR5-independent uptake might be critically involved in the rFlaA: Betv1-mediated induction of proinflammatory and anti-inflammatory cytokine production.
The observed aggregation, which is likely caused by spontaneous self-assembly of flagellin known from flagella biosynthesis, very likely influences uptake of the fused allergen, as well as its subsequent processing and presentation by DCs, and therefore the immunogenicity of the fusion protein. These results are in accordance with our own previous results 6, 20, 23 and the growing evidence that flagellin-containing fusion proteins have superior immune-modulating capacities over the simple mixture of both components shown by others. [9] [10] [11] [12] [13] 29 In this context it was hypothesized that the molecular mass of (fusion) proteins influences processing by the APCs, with high-molecular-weight proteins being processed more effectively. 30 In line with our results, a fusion protein consisting of flagellin C and enhanced green fluorescent protein (EGFP) was found to be more efficiently internalized, processed, and presented by mouse APCs than the respective controls. 30 Consequently, BALB/c mice immunized with this flagellin C:EGFP construct efficiently had specific CD4 and CD8 T-cell responses against the otherwise nonimmunogenic antigen EGFP. 30 As we showed by the inhibition of rFlaA:Betv1 uptake, the observed aggregation of rFlaA:Betv1 also clearly contributes to mDC-derived IL-10 production. In support of this finding, Legge et al 31 reported that the strong aggregation observed for an immunoglobulin chimera carrying the encephalitogenic proteolipid protein 1 induced IL-10 production by macrophages and DCs, whereas the nonaggregated form did not induce IL-10 secretion.
In addition to the possible influences of rFlaA:Betv1 aggregation, rFlaA:Betv1-induced, mDC-derived cytokine secretion was suppressed by inhibition of lysosomal acidification, suggesting that once the fusion protein is taken up into DCs, subsequent protein processing and presentation contribute to its immunemodulating capacity. Notably, rFlaA:Betv1 displayed a higher stability to microsomal digestion than both nonconjugated proteins. In agreement with our previous results for a fusion protein consisting of flagellin and OVA (rFlaA:OVA), 20 these data suggest a diminished but continuous release of rFlaA:Betv1-derived peptides, resulting in prolonged T-cell stimulation. Furthermore, Cuadros et al 30 also described their flagellin C:EGFP fusion protein to activate APCs through both increased internalization of the fusion protein and subsequent differences in processing and presentation.
Thus far, the mechanisms by which flagellin fusion proteins exert their immune-modulating effects remained mostly unknown. Uematsu et al 19 reported a direct stimulation of CD11c
1
TLR5
1 cells and TLR5 signaling to be necessary for the adjuvant activity of flagellin fusion proteins, suggesting that activation of CD11c
1
TLR5
1 cells in the innate immune system is required for the strong immunogenicity of flagellincontaining fusion proteins. Accordingly, our own results with mouse CD11b
B220
2 mDCs support the importance of DCs for innate and adaptive immune responses induced by flagellin fusion proteins. Furthermore, we showed a strong metabolic activity of rFlaA:Betv1-stimulated mDCs.
Additional analysis of the cellular redox status in mDCs confirmed that stimulation with rFlaA:Betv1, but not the mixture of both single proteins, resulted in a high rate of glycolysis, followed by lactic acid fermentation, which is known as the Warburg effect. This increase in metabolic activity was associated with induction of IL-10 production by rFlaA:Betv1. Concordantly, it has been reported that lactate, the end product of the Warburg effect, can enhance IL-10 production while directly reducing IL-12 production in macrophages and DCs. 32 Interestingly, the inhibition of glycolysis in mDCs by 2-DO resulted in dose-dependent inhibition of rFlaA:Betv1-induced cytokine secretion. Therefore we speculate that proinflammatory and anti-inflammatory cytokine secretion in response to this vaccine candidate are differentially regulated by metabolic processes.
Further analysis confirmed that rFlaA:Betv1 stimulation interfered with the metabolism of stimulated cells. Phosphorylation of PRAS40 and mTOR belonging to the mTOR1 complex, as well as the mTOR target protein p70S6 kinase at residue Thr389, suggested an activation of the mTOR1 complex in mDCs stimulated with the fusion protein. Recently, activation of the mTOR pathway by several TLR ligands, such as LPS, CpG, polyinosinic:polycytidylic acid, or flagellin, 28, [33] [34] [35] [36] [37] was implicated to have critical functions in immune cell development and function, 28 suggesting that mTOR is a master regulator of innate immune responses. 38 However, the role of flagellin in metabolic processes is almost not investigated. In line with these findings, the increased metabolic activity in rFlaA:Betv1-stimulated mDCs was shown to be dependent on activation of the mTOR1 complex. This finding is in accordance with literature showing that the mTOR1 complex stimulates glucose uptake through translation of hypoxia-inducible factor 1a. 32 The observed Warburg effect, mTOR phosphorylation, and rFlaA:Betv1-induced IL-10 secretion were dose-dependently inhibited by preincubation of mDCs with the inhibitor of mTOR, rapamycin, and the PI3K inhibitor wortmannin while proinflammatory cytokine secretion remained unchanged. In line with the results obtained for rFlaA:Betv1 in the present study, inhibition of mTOR by rapamycin, while stimulating with either bacteria or purified LPS, was repeatedly shown to enhance IL-12 secretion and boost antigen presentation through increased autophagy while suppressing IL-10 secretion from monocytes/macrophages and DCs. 28, [38] [39] [40] [41] However, the rFlaA:Betv1-induced Warburg effect and IL-10 production were still observed in TLR5-deficient mDCs, suggesting that the observed effects of rFlaA:Betv1 stimulation on mDC metabolism are upstream of the induced TLR5 upregulation in rFlaA:Betv1-stimulated cells. In contrast, the rFlaA:Betv1-induced Warburg effect was reduced and IL-10 production was not observed in MyD88 2/2 mice. MyD88 was shown to be critical for sustained mTOR activation, with S6K1 phosphorylation by mTORC1 promoting physical interaction of mTOR and MyD88, which resulted in interferon regulatory factor 5 and 7 activation. 37, 42 These studies confirm our results that sustained and MyD88-dependent mTOR activation is necessary for rFlaA:Betv12induced IL-10 secretion. In light of these results, we speculate that an unknown MyD88-dependent intracellular flagellin-recognizing receptor or NLRC4 might contribute to the observed rFlaA:Betv12in-duced mDC activation because we also showed that the fusion protein was efficiently internalized.
Recent research suggests a paradigm in which activation of innate immune cells through pattern recognition factors or growth factor receptors triggers an mTOR-dependent reconfiguration of cellular metabolism and modulates central signaling pathways, such as nuclear factor kB (NF-kB), signal transducer and activator of transcription 3 (STAT-3), hypoxia-inducible factor 1a, and peroxisome proliferator-activated receptor g (PPARgamma). 32 Therefore, the mTOR pathway is postulated to serve as a master decision maker to control cellular responses to pathogens by modulating cytokine, chemokine, and type I interferon responses 43 and was hypothesized as an interesting target molecule for the treatment of inflammatory diseases, including allergies. 44 In innate immune cells mTOR is activated after integration of strong activating signals (eg, TLR ligands or CD40 ligand) to limit proinflammatory immune responses through IL-10 secretion. 38, 41, 43 In line with these observations, we believe that the strong initial activation and associated metabolic processes in rFlaA:Betv12stimulated mDCs are sensed by metabolic surveillance mechanisms within the cell, leading to activation of the mTOR1 complex. This subsequently limits the induced immune response through production of IL-10 (for mechanism, see In summary, for the first time, we show that a novel class of vaccines incorporating antigen and flagellin into fusion proteins modulates innate and adaptive immune responses through an mTOR-dependent activation of mDC metabolism. Activation of mDC metabolism promoted immunosuppressive IL-10 production while also inducing potent antigen-specific IgG antibody responses in vivo, which are highly beneficial for the treatment of both infectious and allergic diseases. Additionally, we demonstrated that mTOR differentially regulated proinflammatory and anti-inflammatory cytokine secretion induced by such vaccines. This is the first report of a potential vaccine exerting its immune-modulatory function through enhancing cellular metabolism by the activation of mTOR. Therefore our results provide important insights not only into the mechanisms of immune modulation by flagellin-antigen fusion proteins but also more generally into the development of novel types of vaccines and their complex effects on cells of the immune system.
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Clinical implications: Flagellin fusion proteins are in clinical trials as vaccines for many diseases. We show that modulation of immune responses by flagellin fusion proteins is controlled by an increased metabolic activity of mDCs, resulting in IL-10 secretion.
METHODS
Generation of recombinant proteins
rFlaA from L monocytogenes (accession no. NC_003210) was generated, according to the method of Sch€ ulke et al, E1 and recombinant birch pollen allergen Bet v 1 (accession no. X15877.1) was generated, according to the method of Siebeneicher et al. E2 Both proteins displayed a purity of greater than 99%; correct folding of secondary structure elements, as determined by using circular dichroism spectroscopy; and an endotoxin content of 1.14 pg/mg protein (rflaA) and less than 0.48 pg/mg protein (rBet v 1), respectively (data not shown).
The fusion protein of rFlaA and rBet v 1 (rFlaA:Betv1) was generated by means of cDNA fusion with the cDNAs of both rFlaA and rBet v 1 as templates to generate DNA molecules, which were in part complementary to the sequence of the respective fusion partner (primer sequences to elongate the 39 end of FlaA with a sequence stretch complementary to the 59 end of the Bet v 1 sequence: forward P1, CGCGCGGCAGCCATATGAAAGTAAATACTAATA TCATTAGCTTGAAAACACAAGAATATC; reverse P2, GTAATTGAAAAC ACCCATGCTGTTAATTAATTGAGTT and primer sequences to elongate the 59 end of Bet v 1 with a sequence stretch complementary to the 39 end of the FlaA sequence: forward P3, AACTCAATTAATTAACAGCATGGG TGTTTTCAATTAC; reverse P4, CAGCCGGATCCTCGAGTTAGTTGT AGGCATCG). In a next step the full-length DNA of the fusion protein was generated by using the mixture of both elongated DNA fragments as templates in a PCR reaction (by using primers P1 and P4). The resulting PCR product, spanning the full length of both proteins, was cloned into the NdeI-linearized pET15b expression vector (Novagen, Merck Millipore, Darmstadt, Germany) by using the In-Fusion HD Cloning Kit (Clontech, Saint-Germain-en-Laye, France) and expressed in Escherichia coli BL21 cells for 6 hours at 378C by using 1 mmol/L isopropyl b-D-1-thiogalactopyranosid for induction. The rFlaA:Betv1 fusion protein was purified from bacterial extracts through a combination of immobilized metal ion affinity chromatography and subsequent size exclusion chromatography. The resulting protein displayed a purity of greater 99%; correct folding of secondary structure elements, as determined by using circular dichroism spectroscopy; and an endotoxin content of 1.7 pg/mg protein (data not shown).
In vivo short-term application of proteins
For short-term application, BALB/c mice were injected intraperitoneally with PBS, rFlaA, rBet v 1, rFlaA plus rBet v 1, or rFlaA:Betv1 (all equimolar to 10 mg of rBet v 1) in 200 mL of PBS. Seven hours after injection, anesthetized mice were killed by means of cardiac puncture, and cytokine levels in blood samples were determined by using ELISA with BD OptEIA (BD Biosciences) or Ready-SET-Go! (eBioscience) ELISA kits.
DC stimulation and flow cytometry mDCs were seeded at 3.2 3 10 5 cells/mL in 24-well plates (Thermo Scientific) and stimulated with the indicated equimolar concentrations of rFlaA, rBet v 1, rFlaA plus rBet v 1, or rFlaA:Betv1 for 24 hours. LPS (10 mg/mL; L5886; Sigma-Aldrich) served as a positive control. Supernatants were analyzed for cytokine secretion by means of ELISA with BD OptEIA ELISA Sets (BD Biosciences). mDC activation was assessed by using FACS with anti-mouse fluorescein isothiocyanate (FITC)-conjugated CD40 (clone: 1C10, dilution: 1:100) and phycoerythrin (PE)-conjugated B7-H1 (clone: MIH5, dilution: 1:100), PE-conjugated B7-H4 (clone: 188, dilution: 1:50), FITC-conjugated B7-DC (clone: TY25, dilution: 1:100), or mAbs (eBioscience) or PE-conjugated anti-mouse TLR5 (clone: 85B152. 5 
Experiments with human material
PBMCs from patients with birch pollen allergy, as documented by rhinoconjunctivitis in the spring, birch pollen-specific IgE levels of greater than 3.5 kU A /L (ImmunoCAP, Thermo Fisher Scientific), and positive skin prick test responses to birch pollen (ALK-Abell o, Hørsholm, Denmark), were stimulated with either birch pollen extract or Bet v 1 to expand allergen-specific T cells, as previously described. E3 These allergenspecific T-cell lines were stimulated with equimolar amounts of Bet v 1, rFlaA, or rFlaA:Betv1. After 48 hours, proliferative responses were assessed by means of incorporation of tritiated thymidine. Stimulation indices were calculated as the ratio of counts per minute of stimulated cultures to counts per minute of unstimulated cultures. The study was approved by the local ethics committee (EK 029/2006). Blood donors provided written informed consent.
TLR5 activation assay
HEK 293 cells stably transfected with the murine TLR5 (InvivoGen) were cultured in Dulbecco modified Eagle medium (Biochrome, Berlin, Germany) containing 10% FBS (Biochrome), L-glutamine (0.15 mg/mL), penicillin (100 U/mL), streptomycin (100 mg/mL), and blasticidin (10 mg/mL; InvivoGen). Wild-type HEK 293 cells were cultured without blasticidin, as indicated above. For TLR5 activation assays, 4 3 10 4 cells per well were seeded in 48-well plates and cultured in Dulbecco modified Eagle medium containing 2% FBS, L-glutamine, penicillin, and streptomycin overnight. Cells were stimulated for 22 hours with equimolar amounts of rFlaA, rFlaA:Betv1, or rBet v 1. Subsequently, human IL-8 secreted in the supernatant was quantified by means of ELISA with the BD OptEIA human IL-8 ELISA Set (BD Biosciences).
SDS-PAGE and native PAGE
SDS-PAGE was performed according to the method described by Laemmli (cross-linker C 5 5%, total bisacrylamide 5 15%) E4 under reducing conditions. For native DISC-PAGE, 4% stacking gels and 15% running gels were performed with the following buffers: cathode buffer ( 
Antigen uptake assays
Recombinant proteins were labeled with the Alexa Flour 488 Microscale Protein Labeling Kit (Invitrogen), according to the manufacturer's recommendations. Comparable degrees of fluorescence staining were confirmed by determining the protein concentration based on absorbance at 280 and 494 nm with a NanoDrop ND-1000 (NanoDrop Technologies, Rockland, Del), according to the manufacturer's recommendations, and calculating the degree of labeling with the following formula: DOL 5 ðA 494 3Dilution factorÞ=ð71; 0003Protein concentration½MÞ FIG E9. Proposed mechanism of rFlaA:Betv1-induced mDC activation. rFlaA:Betv1 strongly activates mDCs by TLR5-independent protein uptake, possibly supported by TLR5 activation/TLR5-mediated uptake, resulting in proinflammatory cytokine secretion and expression of both costimulatory and coinhibitory molecules. Strong activation of mDCs upon stimulation with rFlaA:Betv1 also results in a MyD88-dependent activation of the mTOR pathway, which enhances overall cell metabolism while also promoting IL-10 secretion and suppressing IL-12 production. Activation of mTOR by rFlaA:Betv1 also induces a MyD88-dependent upregulation of TLR5, which is associated with an IL-10 secretion. IL-1b and IL-6 secretion are induced independently of rFlaA:Betv1-mediated mTOR activation, possibly through activation of the NLRC4 inflammasome. Solid lines indicate processes that depend on each other, dotted lines describe processes that are independent of each other, blue text indicates speculated connections, and inhibitors of the different pathways used in this study are indicated in red text. p70S6K, Ribosomal protein S6 kinase beta-1; 4E-BP1, eukaryotic translation initiation factor 4E-binding protein 1; FK506, Tacrolimus; NLRC4, NLR family CARD domain-containing protein 4; BM-mDC, bone marrow derived-myloid dendritic cell.
